Showing 18 results for Azad
Ali Davoudi- Kiakalayeh, Mohammad Faranoush, Azadeh Haghbin, Firouz Behboudi,
Volume 6, Issue 1 (Autumn 2013)
Abstract
Background: To evaluate the present status of blood utilization and develop practice guidelines in teaching hospitals in Northern Iran.
Methods: We retrospectively analyzed the amount of blood prepared and used preoperatively for 11 elective procedures, from March 2010 to March 2011 in teaching hospitals in Northern Iran. Study variables included the crossmatch transfusion ratio, the transfusion index and transfusion probability. The crossmatch transfusion ratio and the transfusion index were also calculated for each type of elective surgery performed during the study period.
Results: During the study period, 5981 units of blood were crossmatched for 1970 cases. Out of these1835 units of blood were transfused which means only 31% of blood was utilized while 69% was not needed. The overall crossmatch transfusion ratio for 11 procedures was 31.1 and many procedures were found to have a high transfusion ratio and a low transfusion index.
Conclusion: The introduction of maximum surgical blood-order schedule will lead to a reduction of blood outdating and crossmatch workload. Although routine cross match seems necessary for two elective surgical procedures (coronary artery bypass graft and hysterectomy) in vast majority of elective surgical procedures type and antibody screening is recommended.
Keywords: Blood, transfusion, crossmatch, ratio, probability, index.
N Shakibazad , M Karimi ,
Volume 6, Issue 4 (Summer 2014)
Abstract
This is a picture review of a case of orbital rhabdomyosarcoma. The course of patients diagnosis, treatment and outcome is briefly presented.
Daneshmand Ar, Forouzandeh H, Azadi M, Cheraghzadeh Dezfuli S,
Volume 7, Issue 2 (Winter 2015)
Abstract
Background: This study made an attempt to make the quantitative and qualitative evaluation of hematological research output in five Islamic countries Iran, Turkey, Malaysia, Saudi Arabia and Egypt which have the most scientific productions from 1996-2013.
Materials and Methods: The current study was carried out during the 1st to 31st of September, 2014 in Blood Transfusion Research Center, Shiraz, Iran. This bibliometric study evaluated quantities and qualities of publications on hematological researches based on SCImago Journal Ranking, for over 17 years (1996- 2013). Strategy of the research was based on the keyword “hematology “. Neither language nor document type restrictions were considered. Data were extracted, tabulated, and compared to identify the ranks as well as trends. The ranking and analyzing indicators included were: ‘number of documents’, ‘citable documents’, ‘citation’, ‘self-citation’, ‘cites per documents’, ‘H-index’, ‘sited documents’, and ‘international collaboration’ .
Results: The 5 Islamic countries published a total of 6914 documents in the field of hematology in this period. This number represents 0.248 % of the total documents produced globally in the field of hematology. Results revealed an increase in the number of publications and citable documents for these countries during 1996-2013. Comparison among these countries showed that Turkey, Iran, Egypt have the highest number of documents and citable documents, respectively. Furthermore Turkey and Iran led qualitative indicators like H-index and citation.
Conclusion: Despite considerable improvement in recent years these Islamic countries should further support their scientific institutes to increase the quantity and quality of hematology publications.
Keywords: Islamic countries, hematology, SCImago Journal Ranking, bibliometric study.
Seyedeh Masumeh Hashemi, Ghamartaj Khanbabaee, Sara Salarian, Mohammadreza Fariborzi, Azadeh Kiumarsi,
Volume 9, Issue 2 ( June 2017 2017)
Abstract
Background: Red cell distribution width (RDW) is a routine laboratory measure that could be used as a predictor of mortality in critically ill patients. Identification of patients at risk for mortality early in the course of PICU admission is an important step in improving the outcome. We aimed to assess the use of RDW as an early biomarker for outcome in pediatric critical illnesses.
Methods: A retrospective study by extracting administrative and laboratory data from patients admitted to PICU of an academic pediatric teaching hospital was accomplished. After exclusion of 64 patients according to our exclusion criteria, 304 pediatric patients with PICU admissions over the 6 months of study period were included in the study.
Results: The mean RDW for all patients was 14.9%±2.5%. PICU mortality was 13.3%. The rate of mortality in the quartile of RDW>15.7% was 20.1%. Elevated RDW was associated with longer duration of PICU admission (P<0.001). Tracheal intubation and ventilator support was needed in 34.2% of the patients. This was also correlated with elevated RDW (P=0.043).
Conclusion: We observed that higher RDW was strongly linked to higher mortality risk in pediatric patients admitted in PICU. Higher RDW was associated with longer duration of PICU admission.
Hamid Gholipour, Saeid Abroun, Mehrdad Noruzinia, Sasan Ghaffari, Amirhosein Maali, Mehdi Azad,
Volume 10, Issue 4 ( December 2018 2018)
Abstract
Background: Epigenetic modifications, such as methylation can occur in multiple myeloma. SMG1is an important gene involved in cell growth which defect in methylation of its promoter leads to reduction of cell apoptosis and uncontrolled proliferation. In this study, we identified the methylation status of the SMG1 gene promoter in patients with multiple myeloma.
Methods: Methylation status of SMG1 promoter in 9 patients with multiple myeloma and 4 healthy subjects as control was determined by Methylation-specific PCR (MSP) method.
Results: SMG1 promoter in all myeloma patients was hemi-methylated. Meanwhile, in healthy subjects, two cases were hemi-methylated and the other two were normal.
Conclusion: The results of this study indicated that the prevalence of SMG1 promoter methylation in patients with multiple myeloma was higher than general population which could be important in understanding the pathogenesis of the disease.
Amir Ghasemi-Jangjoo, Mohammad Mirza-Aghazadeh-Attari, Seyed Ali Mousavi-Aghdas,
Volume 11, Issue 2 ( June 2019 2019)
Abstract
Background: Hypofractionated radiotherapy (HF) method was introduced to overcome the quickly growing tumor cells as well as shortening whole treatment course in solid tumors such as breast cancers. Here, we compared the incidence of dermatitis and pharyngitis among patients undergoing HF versus conventional fractionationated (CF) radiation therapy following surgery for breast cancer.
Methods: During this prospective study, women who had undergone breast surgery since 2015-2017 were included in the initial sample population. 40 patients were included for analysis in each arm of CF and HF. Patients treated by CF received 50 Gy with 2.0 Gy per each fraction session and in group of HF; 42.4 Gy was delivered in 2.66 Gy per fraction sessions for 3 months. Severity of acute dermatitis and pharyngitis was recorded for all patients in both groups based on regular examinations during and after the radiation therapy.
Results: 18 out of 40 patients in the conventional group experienced dermatitis of which 11 and 3 were grade 2 and 3, respectively. In the HF group, 8 experienced only grade 1 acute dermatitis. Thus, acute radiation-induced dermatitis occurred more frequently (P=0.017) and more severely (P=0.002) in the conventional group within 3 months of follow-up. There was no statistically significant difference in incidence of pharyngitis between the two groups.
Conclusion: There was a statistically significant difference in occurrence of dermatitis between the two groups of conventional radiotherapy and those who received hypofractionated radiation. Incidence and severity of dermatitis was more common in those who received conventional radiotherapy in comparison to hypofractionated method.
Mohammadreza Bordbar, Fazl Saleh, Omid Reza Zekavat, Mitra Basiratnia, Gholamreza Fathpour, Soheila Zareifar, Mahdi Shahriari, Mehran Karimi, Nader Shakibazad,
Volume 11, Issue 2 ( June 2019 2019)
Abstract
Background: Nephrotoxicity secondary to doxorubicin (DOX) may be associated with high morbidity and mortality rates. We aimed to assess the efficacy of Deferoxamine (DFO) in preventing DOX-induced nephrotoxicity in pediatric malignancy.
Methods: This Parallel-group randomized clinical trial was done on 62 children aged 2-18 years who had new onset malignancy treated with DOX. They were randomly assigned in three groups; group 1 (no intervention, n=21), group II (DFO 10 times DOX dose, n=20), group III (DFO 50mg/kg, n=21). Patients in the intervention groups received DFO concomitant with DOX 8-hour intravenous infusion in each chemotherapy course. Blood urea nitrogen, serum creatinine, electrolytes, calcium, phosphorus, magnesium and albumin levels, urine microalbumin, urine protein/creatinine ratio, and urine N-acetyl-β-D- glucosaminidase (NAG) as well as findings of kidney ultrasonography were compared between the groups after the last course of chemotherapy. The primary outcome was to compare the radiologic and serologic markers of glomerular and tubular damage between the 3 groups.
Results: Sixty patients were analyzed. Patients treated with DFO 10 times the dose of DOX had significantly lower urine NAG level compared to the control group (P=0.032). No significant renal damage was reported in their ultrasonography in the 3 groups. DFO was safely tolerated without any adverse effect.
Conclusion: DFO with 10-times the DOX dose may effectively prevent DOX-induced nephrotoxicity at least at the molecular level. Increasing the dose of DFO is not accompanied by better efficacy.
Trial registration: IRCT2016021915666N3
Amirhosein Maali, Elaheh Ferdosi-Shahandashti, Mehdi Azad,
Volume 11, Issue 3 ( September 2019 2019)
Abstract
Ali Dideban, Ensiyeh Seyedrezazadeh, Akbar Sharifi, Bahareh Abd-Nikfarjam, Morteza Sadeghi,
Volume 12, Issue 1 ( March 2020 2020)
Abstract
Background: Lung cancer is the first cause of cancer deaths worldwide. Polymorphisms in microRNAs genes affect their structure and their attachment to target genes. The purpose of the present study was to investigate the association of miR-146a rs2910164 polymorphism with the risk of non-small cell lung cancer (NSCLC) in Iranian patients.
Methods: This case-control study was performed among 103 patients with lung cancer and 100 healthy controls. The genotyping of miR-146a rs2910164 polymorphism was assayed by polymerase chain reaction–restriction fragment length polymorphism (PCR–RFLP) and a number of samples were sequenced for final approval.
Results: A significant association was found between rs2910164 polymorphism CG genotype and risk of lung cancer progression in dominant models (CG vs. GG: OR=1.855, CI=1.09-3.33, P=0.03). There was no association between the C allele and frequency of rs2910164C>G polymorphism and risk of lung cancer (C vs. G: OR=1.54, CI=0.97-2.44, P=0.08).
Conclusion: There was a significant association between miR-146a rs2910164 polymorphism and lung cancer in Iranian population. This polymorphism can be considered as a risk factor of non-small cell lung cancer.
Nader Shakibazad, Mohammadreza Bordbar,
Volume 14, Issue 1 ( March 2022 2022)
Abstract
Introduction: The objective of this study is to determine the major causes of early death in acute lymphoblastic leukemia (ALL).
Methods: The following databases including PubMed, EMBASE, Science Direct and Google Scholar were searched for following terms: “acute lymphoblastic leukemia”, “early mortality”, “early death “ and “death in induction phase “. Inclusion criteria were all studies about the etiologies of early mortality in children with acute lymphoblastic leukemia. Early death means death occurs within 30 days of starting induction chemotherapy.
Results: In total, 12 studies fulfilled inclusion criteria.7561 children under 18 years of age were studied in this review. Of these, 354 patients died during the induction phase of therapy. The early mortality rate was 4.6%±4.8. The most common cause of early death was an infection (52.5%), which was mainly bacterial. The second leading cause was bleeding (15%), and tumor lysis syndrome (4%) was the third most common cause. The other causes were septic shock (2%), hyperleukocytosis (2%), encephalopathy (1.7%), cardiomyopathy (1.7%), chemotherapy-related toxicity (1.2%), and thrombotic events (0.6%).
Conclusion: It is needed to advance supportive care to prevent infection by starting Intravenous immunoglobulin for infant and prophylaxis against Pneumocystis jiroveci with trimethoprim/sulfamethoxazole in neutropenic patients during induction, and bleeding by transfusion support.
Dr Mohammadreza Bordbar, Dr Gholamreza Fathpour, Dr Seyed Mohsen Dehghani, Sezaneh Sezaneh Haghpanah, Hossein Molavi Vardanjani, Mohammadreza Fattahi, Dr Mahdi Shahriari, Dr Nader Shakibazad,
Volume 14, Issue 3 ( September 2022 2022)
Abstract
Background: This study aimed to investigate the protective role of deferoxamine (DFO) in the prevention of doxorubicin (DOX)-induced hepatic fibrosis in children.
Methods: In this prospective randomized controlled trial, 61 treatment-naïve children (2-18 years) with different types of cancer who referred to a tertiary teaching hospital in the South of Iran were enrolled. They were randomly assigned to 3 groups; group 1 (control, n=21), group 2 (DFO 10 times DOX dose, n=20), group 3 (DFO 50mg/kg, n=20). DFO was administered as an 8-hour continuous intravenous infusion during and after DOX infusion in each chemotherapy cycle. Non-invasive serum markers of liver fibrosis, including AST-to-platelet ratio index (APRI), Fibrosis-4 (FIB-4) score and Fibro Test were measured in each individual. Besides, hepatic Fibro Scan was used after the last course of chemotherapy to estimate the fibrosis degree.
Results: Alanine aminotransferase was mildly increased after treatment compared to before treatment. The treatment with DFO 10 times DOX dose was associated with a significant decline in post-treatment APRI (adjusted odds ratio 0.17; 95% confidence interval 0.03- 0.84. P-value=0.015). The METAVIR fibro scores were in the F0-F1 zone in all participants, and the results were comparable in study groups. No adverse drug effects were reported in the treatment groups.
Conclusion: DOX may not lead to severe liver fibrosis if the maximum cumulative dose allowed is not exceeded. DFO at the dose of 10 times of DOX dose may have a potential protective role against liver fibrosis. More studies with longer follow-up are needed to further assess this issue.
Miss Forouzan Bahmani, Miss Shima Azadpour, Miss Atieh Pourbagheri-Sigaroodi, Dr Davood Bashash,
Volume 14, Issue 3 ( September 2022 2022)
Abstract
The latest treatments have improved outcomes for patients with hematological malignancies, but relapse, treatment resistance and particularly side effects still remain as common limitations of these treatments. Given the disadvantages of the existing conventional therapeutic methods, developing more effective drugs with less toxicity and side effects is of paramount importance. Medicinal herbs have historically proven their worth as a pool of potential therapeutic agents for leukemia and lymphoma, and today they still represent a rich source for the recognition of new drug leads. The role of the positive synergistic effects of plant-derived natural products and common chemotherapeutic drugs is also considered as one of the rational reasons for paying attention to the medicinal plants in recent chemoprevention and chemotherapeutic investigations. Noteworthy, targeted delivery of plant-derived natural products via the incorporation of nanoparticles or antibodies would be a major step to improve their bioavailability and then to increase their therapeutic effects. In this study, we reviewed plant-derived agents approved and/or under investigation for hematological malignancies.
Dr Mojtaba Malek, Dr Mohammad E. Khamseh, Dr Pooya Faranoush, Dr Nahid Hashemi-Madani, Dr Neda Rahimian, Dr Fariba Ghassemi, Dr Mohammad Reza Foroughi-Gilvaee, Dr Negin Sadighnia, Dr Ali Elahinia, Dr Mohammad Reza Rezvany, Dr Dorsa Fallah Azad, Dr Mohammad Faranoush,
Volume 16, Issue 1 (March 2024 2024)
Abstract
The health-related quality of life and management of patients with thalassemia has significantly improved in recent years due to standard treatments and safe blood transfusions with effective chelation therapy to reduce iron overload. Transfusion-dependent thalassemia is associated with numerous skeletal abnormalities, including osteoporosis, which is a significant cause of morbidity in these patients. Osteoporosis is characterized by low bone mass and an increased risk of fractures, particularly in the lumbar spine and in patients with extramedullary hematopoiesis. It remains a significant problem in adult transfusion-dependent thalassemia, particularly in patients under chelation therapy. A fracture history is significantly associated with lower Dual-Energy X-ray Absorptiometry (DEXA) T/Z scores, which decrease with age. Improved management and modern treatments for transfusion-dependent thalassemia patients with osteoporosis should be prioritized to prevent bone fractures and improve quality of life in older age.
Dr Fariba Ghassemi, Dr Mohammad E. Khamseh, Dr Negin Sadighnia, Dr Mojtaba Malek, Dr Nahid Hashemi-Madani, Dr Neda Rahimian, Dr Pooya Faranoush, Dr Ali Elahinia, Dr Vahid Saeedi, Dr Dorsa Fallah Azad, Dr Mohammad Faranoush,
Volume 16, Issue 1 (March 2024 2024)
Abstract
ntroduction: Thalassemia, particularly α and β types, are characterized by mutations causing varied clinical manifestations such as anemia, skeletal deformities, and iron accumulation. Patients with transfusion-dependent thalassemia (TDTs) often face growth and puberty complications, which are influenced by the disease’s type and severity. These disruptions not only result from chronic anemia, iron chelation therapy, and endocrinopathies but also significantly impact the patient’s quality of life.
Methods: A comprehensive guideline was formulated through a systematic literature review and stakeholder engagements. The protocol emphasizes diagnosing and managing growth and puberty disorders in TDT patients, integrating consistent monitoring, documentation, and patient-specific assessments.
Results: The guideline proposes a detailed monitoring schedule from birth to adulthood, focusing on growth velocity norms and referral criteria to pediatric endocrinologists. It outlines protocols for hormone treatments in cases of delayed or arrested puberty, with distinctions for boys and girls. The treatment approach is multidisciplinary, combining growth monitoring, hormone therapy, and potential surgical interventions. The complexities demand continuous management, with treatment plans tailored to individual patient needs.
Conclusions: The research provides a pivotal national protocol for addressing growth and puberty anomalies in TDT patients, aiming to enhance their well-being and standardize care. The emphasis on proactive, individualized strategies will bolster healthcare outcomes and reduce associated costs.
Saeed Turkmen, Neda Karami Chermahini, Amirhosein Maali, Mohammad Reza Keramati, Mohammad Hossein Ahmadi, Mehdi Azad, Samaneh Borouman-Noughabi,
Volume 16, Issue 3 (September 2024 2024)
Abstract
Background: Aberrant DNA methylation is a key epigenetic alteration observed in multiple cancers. Acute myeloid leukemia (AML), a prominent form of hematopoietic cancer, is characterized by abnormal proliferation and differentiation of myeloid progenitor cells. This study focuses on examining the methylation status of the CpG islands in the DNMT1 and CDX2 promoter regions and exploring their correlation with prognostic hematological laboratory parameters across three phases of AML: newly diagnosed, undergoing treatment, and in remission.
Material and methods: This follow-up case-control study recruited 11 new cases of confirmed AML admitted to Shariati Hospital in Tehran. All patients received AML treatment according to FDA protocol. The samples (peripheral blood) were collected before medication (new case phase), during medication (under treatment phase), and in the remission phase. Then, genomic DNA was extracted and treated with the bisulfite treatment method. Then, methylation-specific PCR (MSP) was conducted to amplify treated DNAs using two methylated and unmethylated primers related to their promoters' DNMT1 and CDX2 CpG- islands. All statistical analysis was performed using SPSS v.25.
Results: The results of the methylation pattern of DNMT1 gene promoter CpG islands in the present study show that the hemimethylated pattern of the DNMT1 gene promoter is predominant in control (100%), new case phase (90.9%), under treatment phase (72.7%), and remission phase (100%). In the case of the CDX2 gene, the unmethylated pattern is predominant in control (57.14%), new case phase (72.7%), under-treatment phase (90.9%), and remission phase (81.8%). These differences were not statistically significant. No methylated pattern was observed in the control group, and different phases of AML were used for DNMT1 and CDX2. Also, the methylation status of DNMT1 and CDX2 were not correlated with prognostic hematological laboratory parameters.
Conclusion: The methylation patterns of CDX2 and DNMT1 are not different in healthy individuals and AML patients, as well as in different phases of AML. Also, the methylation patterns of CDX2 and DNMT1 cannot help determine the prognosis of AML patients through changes in hematological laboratory parameters.
Mahdieh Ahmadi Kamalabadi, Somayeh Kazempour, Asieh Fatemidokht, Mikaeil Molazadeh, Fereshteh Koosha,
Volume 16, Issue 4 (December 2024 2024)
Abstract
Cancer is estimated to overtake cardiovascular diseases and take the top spot as the leading and most important cause of mortality globally in the near future. Given the importance of early diagnosis to reduce mortality, many efforts have been made to discover a theranostic system for simultaneous cancer diagnosis and treatment. So far, the use of nanotechnology has greatly contributed to the improvement and development of these systems. Meanwhile, dendrimer nanoparticles have attracted considerable attention in medical research due to their unique properties. Poly(amidoamine) (PAMAM) dendrimers have become the primary category of dendrimers and have been widely studied for their possible application in cancer treatments. These nanoparticles have features including interior cavities and peripheral functional groups that allow the encapsulation of diverse medications or diagnostic agents. As a result, these particles can function as efficient nanocarriers and vectors for medical applications. This capability allows for the resolution of the obstacles presented by the tumor microenvironment. The prospective use of multifunctional PAMAM holds promise in enabling thorough monitoring of different stages of treated cancer tissue, hence providing substantial support in the early detection and prediction of tumor response. The primary focus of this study will be to investigate the most recent developments of PAMAM dendrimers in the field of cancer theranostics. The employment of NPs in anticancer medicine administration for radiation treatment, chemotherapy, and diagnostic imaging is underscored due to its significant potential.
Azadeh Taghizadeh, Roham Salek,
Volume 17, Issue 1 (March-2025 2025)
Abstract
Background: Limited data exist on complications and treatment outcomes following brachytherapy after chemoradiation in esophageal cancer. This study aimed to assess complications and treatment outcomes after intraluminal brachytherapy post-definitive chemoradiation.
Methods and Materials: This retrospective cohort study included esophageal cancer patients treated at Imam Reza Radiotherapy Center, Mashhad, Iran (2016-2023). Patients received chemoradiotherapy with paclitaxel-carboplatin, cisplatin-irinotecan, or cisplatin-5-FU (5-6 weeks), with a total radiation dose of ≥45 Gray. After a two-week rest, they underwent HDR brachytherapy with cobalt-60 and were followed monthly for one year.
Results: A total of 125 patients (mean age: 71.08±10.67 years) were evaluated. The overall survival (OS) and disease-free interval (DFI) were 47.26 and 22.62 months, respectively. The most common tumor location was the middle esophagus, and the most common grade was G2. An ECOG score <2 was observed in 96 patients. No significant association was found between OS and DFI with tumor location, grade, dysphagia level, or functional index. However, brachytherapy dose, radiotherapy dose, and chemotherapy regimen were significantly associated with OS, but not with DFI. Post-treatment complications occurred in 98 patients, including local recurrence in 39 cases. Patients without complications had a mean DFI and OS of 54 and 55 months, respectively, while those with complications had 37 and 50 months. Complications were significantly associated with DFI but not with OS. Complete response was seen in 106 patients, significantly correlating with OS (P=0.003) and DFI (P<0.001). Patients with local and distant recurrence had an 11-fold higher mortality risk.
Conclusion: Intraluminal brachytherapy after definitive chemoradiation plays a crucial role in treatment management for esophageal cancer. It should be considered as a treatment option, but further studies with larger sample sizes are needed for routine implementation.
Abolfazl Jafari-Sales, Elham Nozohour-Leilabadi, Maryam Safari, Maryam Farahnaki-Sadabadi, Negin Yaghoubi-Azar, Mehrdad Pashazadeh,
Volume 17, Issue 1 (March-2025 2025)
Abstract
A number of variables may influence the development and spread of lung cancer (LC), one of the most prevalent and fatal cancers in the world. In this context, viruses are important, especially the human papillomavirus (HPV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), influenza virus (IV), and cytomegalovirus (CMV). These viruses can influence the development of LC through metabolic alterations, immune response suppression, and disruption of the tumor microenvironment (TME). Specifically, HPV may contribute to LC through genetic effects, while EBV can induce molecular changes in cells. HIV, by suppressing the immune system and increasing the risk of secondary infections, may create conditions conducive to the development of lung tumors. IV and CMV can also play a role in accelerating tumorigenic processes by impacting the immune system and promoting inflammation. This review article examines the various mechanisms by which viruses are involved in LC and their association with the progression of lung tumors. Additionally, the role of vaccination in preventing LC, particularly in individuals infected with specific viruses, is explored.
